These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36891042)

  • 21. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
    Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-individualization Efficiently Maintains Sufficient Exposure to Methotrexate without Additional Toxicity in High-dose Methotrexate Regimens for Pediatric Acute Lymphoblastic Leukemia.
    Shen YQ; Wang ZJ; Wu XY; Li K; Wang ZJ; Xu WF; Zhou F; Jin RM
    Curr Med Sci; 2022 Aug; 42(4):769-777. PubMed ID: 35864414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
    Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen.
    Kroll M; Kaupat-Bleckmann K; Mörickel A; Altenl J; Schewel DM; Stanullal M; Zimmermann M; Schrappe M; Cario G
    Haematologica; 2020 Apr; 105(4):1013-1020. PubMed ID: 31371414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
    Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
    J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
    Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
    Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoalbuminemia and not undernutrition predicts high-dose methotrexate-induced nephrotoxicity in children with acute lymphoblastic leukemia in resource-constrained centers.
    Khera S; Sharma G; Negi V; Shaw SC
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29738. PubMed ID: 35451162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of Delivering High-Dose Methotrexate in Adolescent and Adult All Patients: A Retrospective Study.
    Shenoy R; Panda G; Bonda VNA; Sengar M; Thorat J; Jain H
    Indian J Hematol Blood Transfus; 2022 Oct; 38(4):638-642. PubMed ID: 36258731
    [No Abstract]   [Full Text] [Related]  

  • 29. High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
    Ebid AIM; Hossam A; El Gammal MM; Soror S; Mangoud NOM; Mahmoud MA
    J Chemother; 2022 Oct; 34(6):381-390. PubMed ID: 34895107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
    Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
    J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.
    Yang CH; Yang LJ; Jaing TH; Chan HL
    Int J Dermatol; 2000 Aug; 39(8):621-3. PubMed ID: 10971734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK.
    Bielack S; Fox CP; Hoang-Xuan K; Giró-Perafita A; Rizzari C
    Health Sci Rep; 2024 Jan; 7(1):e1749. PubMed ID: 38186937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
    Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
    Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety of administration of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients.
    Reggev A; Djerassi I
    Cancer; 1988 Jun; 61(12):2423-8. PubMed ID: 3259154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
    Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
    Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
    Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
    Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
    J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study.
    Khera S; Mahajan D; Barbind K; Dhingra S
    Cancer Chemother Pharmacol; 2023 Apr; 91(4):331-336. PubMed ID: 36951972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.